New Phase 3 Trial of Blisibimod for Severe Lupus Begins

Source: Lupus News Today

Anthera Pharmaceuticals reported that the company’s Phase 3 clinical trial of blisibimod in patients with severe systemic lupus erythematosus (SLE) began recently with researchers screening the study’s first patient.

Called CHABLIS 7.5, the study is the second Phase 3 trial to explore the drug in lupus patients with and without lupus related kidney disease. Blisibimod will be compared to placebo in a double-blind manner; patients will be randomized to either of the two groups. The study focuses on subjects with continued symptoms despite treatment with glucocorticoid corticosteroid drugs.

For more information, contact  Monica Gangal at 510-856-5600 ext 5574 or email mgangal@anthera.com.